Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients

Transplantation

Volumn 87, Issue 6, 2009, Pages 896-906

  Crop, Meindert J ^a   Baan, Carla C ^a   Korevaar, Sander S ^a   Ijzermans, Jan N M ^a   Alwayn, Ian P J ^a   Weimar, Willem ^a   Hoogduijn, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti donor reactivity; Immunosuppression; Kidney transplantation; Mesenchymal stem cell; Mixed lymphocyte reaction

Indexed keywords

COMPLEMENTARY DNA; IMMUNOSUPPRESSIVE AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RNA; STEROID; TACROLIMUS; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; NATURAL KILLER T CELL; ORGAN DONOR; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ADIPOSE TISSUE; AGED; BLOOD; CYTOLOGY; IMMUNOLOGY; LIVING DONOR; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MIXED LYMPHOCYTE CULTURE; T LYMPHOCYTE; TRANSPLANTATION;

ADIPOSE TISSUE; ADULT; AGED; FEMALE; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; T-LYMPHOCYTES; TISSUE AND ORGAN HARVESTING;

EID: 65549154385     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819b3d72     Document Type: Article

References (32)

1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143.
2. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838.
3. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722.
4. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815.
5. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34-derived and monocyte- derived dendritic cells. J Immunol 2006; 177: 2080.
6. Batten P, Sarathchandra P, Antoniw JW, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves. Tissue Eng 2006; 12: 2263.
7. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390.
8. Dazzi F, van Laar JM, Cope A, et al. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007; 9: 206.
9. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42.
10. Inoue S, Popp FC, Koehl GE, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81: 1589.
11. Crop MJ, Baan C, Weimar W, et al. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 2008; [Epub ahead of print].
12. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5: 485.
13. Maccario R, Moretta A, Cometa A, et al. Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant 2005; 11: 1031.
14. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16: 597.
15. Hoogduijn MJ, Crop MJ, Peeters A, et al. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am J Transplant 2008; 9: 222.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402.
17. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11.
18. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47.
19. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386.
20. Rasmusson I, Ringden O, Sundberg B, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208.
21. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4- T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516.
22. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74.
23. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367.
24. Hendrikx T, Van Gurp E, Mol W, et al. Sequential analysis of CD4-CD25bright- FoxP3- T-cells in renal allograft patients reveals no intrinsic defect in their regulatory capacity [abstract]. Am J Transplant 2007; 7: S2.
25. Bestard O, Cruzado JM, Mestre M, et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3- regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179: 4901.
26. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19: 345.
27. Benvenuto F, Ferrari S, Gerdoni E, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007; 25: 1753.
28. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181: 3933.
29. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389.
30. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890.
31. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 2006; 108: 2114.
32. Sbano P, Cuccia A, Mazzanti B, et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008; 300: 115.